Detail
| LncRNA Name | DANCR |
| Synonyms | DANCR, AGU2, ANCR, KIAA0114, SNHG13, lncRNA-ANCR |
| Region | GRCh38_4:52712404-52720351 Sequence |
| Ensembl | ENSG00000226950 |
| RefSeq | NR_024031 |
| Circulating | ✘ |
| Drug-resisitant | ✔ |
| Prognostic | ✘ |
| MiRNA | ✔ |
| Variant | ✘ |
| TF | ✘ |
| Methylation | ✘ |
| Cancer Name | malignant glioma |
| ICD-0-3 | M9380/3 |
| Methods | qPCR, Western blot, Luciferase reporter assays, in vitro knockdown etc. |
| Sample | cell lines (U87MG, U251MG, LN18,U138MG) |
| Expression Pattern | up-regulated |
| Function Description | Long noncoding RNA DANCR mediates cisplatin resistance in glioma cells via activating AXL/PI3K/Akt/NF-kB signaling pathway. DNACR also attenuated cisplatin-induced cell apoptosis in vitro and in vivo. DANCR upregulated AXL via competitively binding miR-33a-5p, miR-33b-5p, miR-1-3p, miR-206, and miR-613. Through upregulating AXL, DANCR activated PI3K/Akt/NF-kB signaling pathway in glioma cells. Inhibiting AXL/PI3K/Akt/NF-kB signaling pathway reversed the effects of DANCR on cisplatin resistance.DANCR promotes cisplatin resistance via activating AXL/PI3K/Akt/NF-kB signaling pathway in glioma.DANCR would be a potential biomarker for predicting cisplatin sensitivity and a therapeutic target for enhancing cisplatin efficacy in glioma. |
| Pubmed ID | 29572052 |
| Year | 2018 |
| Title | Long noncoding RNA DANCR mediates cisplatin resistance in glioma cells via activating AXL/PI3K/Akt/NF-kB signaling pathway. |
| External Links |
| Links for DANCR | GenBank HGNC lncrnadb Noncode |
| Links for malignant glioma | Omim Cosmic |
CopyRight © College of Bioinformatics Science and Technology, Harbin Medical University, China.